Angiodynamics (ANGO) Cost of Revenue (2010 - 2026)

Angiodynamics' Cost of Revenue history runs 17 years deep, the most recent figure standing at $39.8 million for Q2 2026.

• Quarterly Cost of Revenue rose 4.99% year-over-year to $39.8 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $145.3 million (up 7.78% YoY) and the FY2026 annual result came in at $145.3 million, up 7.78% from the prior year.
• Cost of Revenue was $39.8 million for Q2 2026 at Angiodynamics, up from $36.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $44.7 million in Q2 2023 and bottomed at $30.8 million in Q3 2024.
• A 5-year average of $37.2 million and a median of $38.3 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue grew 17.44% — and 2024, when it retreated 27.4%.
• Angiodynamics' Cost of Revenue stood at $40.4 million in 2022, then retreated by 3.82% to $38.8 million in 2023, then dropped by 15.13% to $32.9 million in 2024, then advanced by 5.19% to $34.6 million in 2025, then gained by 14.96% to $39.8 million in 2026.
• Business Quant data shows ANGO's Cost of Revenue at $39.8 million in Q2 2026, $36.9 million in Q1 2026, and $34.6 million in Q4 2025.